Morphine is viewed as one of the classical treatments for intractable pain, but its role is limited by side effects, including analgesic tolerance. A few chemokines have been reported to be engaged in the mechanisms of morphine tolerance. However, the exact roles of CXC chemokine 11 (CXCL11) in chronic morphine tolerance remain unknown. In this study, Walker 256 mammary gland carcinoma cells were inoculated into the tibia of rats to provoke cancer-induced bone pain. Then, morphine was intrathecally administered twice daily for seven consecutive days to induce drug tolerance. We found that the level of CXCL11 in lumbar spinal cord was increased during the development of morphine tolerance in cancer-induced bone pain rats. Meanwhile, CXCL11 was co-localized with markers of astrocytes and neurons in the spinal cord. Inhibition of CXCL11 by neutralizing antibodies could remarkably attenuate the degree of morphine tolerance and decrease the activation of astrocytes. Moreover, blocking astrocyte activation by D, LFluorocitric acid could distinctly alleviate morphine tolerance and reduce the expression of CXCL11. Finally, morphine stimulation could induce the release of CXCL11 by cultured astrocytes and neurons in vitro. In summary, our results provide evidence that spinal CXCL11 plays a powerful modulatory role in the development of morphine tolerance through cross-talking between astrocytes and neurons.
Cancer-induced bone pain (CIBP) occurs in patients with primary bone cancer or secondary bone metastasis from distant sites such as breast, prostate, and lung. CIBP is a severe clinical condition which is very difficult to treat (Goblirsch et al. 2005) . Patients with skeletal malignancies suffer from severe pain, which results in increased morbidity and decreased quality of life (Bruera and Kim 2003) . Although a variety of treatments are used to alleviate bone cancer pain, including non-steroidal anti-inflammatory drugs, bisphosphonates, radiation, and surgical interventions (Levy 1996; Cherny 2000) , opioids remain the mainstay analgesic therapy (Mercadante 1999; Ruiz-Garcia and Lopez-Briz 2008) . It is worth noting that morphine dose sometimes has to be escalated because of drug tolerance (Schug and Auret 2008) , which hinders the clinical utility of opioids in managing severe pain syndromes (Ossipov et al. 2004) . To date, the underlying mechanisms of morphine tolerance are not completely understood.
Chemokines are a large family of cytokines released by multiple cells (mainly monocytes, macrophages and endothelial cells etc.) which play pivotal roles in leukocyte trafficking under physical condition as well as leukocyte recruitment during inflammation. Meanwhile, chemokine receptors are members of G-protein-coupled receptor superfamily. Chemokines and their receptors have been categorized into four subclasses of family: C, CC, CXC, and CX3C (Charo and Ransohoff 2006) . Accumulated evidence shows that some chemokines may attenuate the analgesic effect of morphine, giving rise to the development of morphine antinociceptive tolerance. Previous study has shown that chemokine monocyte chemoattractant protein-1 from spinal neurons participates in the mechanism of morphine tolerance by regulating microglial activation (Zhao et al. 2012) . Administration of anti-CX3CR1 neutralizing antibody with morphine strengthens acute morphine analgesia and diminishes the development of morphine tolerance (Johnston et al. 2004) . Furthermore, pretreatment with CCL5 or CXC chemokine 12 (CXCL12), followed by opioid injection into periaqueductal gray could inhibit opioid-induced analgesia (Szabo et al. 2002) . In addition, our previous study demonstrated that up-regulating CXCL10/CXCR3 could interfere with morphine analgesia, while CXCR3 antagonist could attenuate pain behaviors in bone cancer pain rats (Ye et al. 2014; Guan et al. 2015) .
Particularly, CXCL11 is not only a major effector for Tcell chemotaxis in the pathophysiology of neuroinflammatory disorders, but also plays a crucial role in the migration of activating T cells during interferon(IFN)-dominated immune responses (Cole et al. 1998) . Although CXCL11 shares the same receptor CXCR3 with CXCL10 (IP-10) and CXCL9 (Mig), it exhibits the significantly higher affinity to CXCR3 and greater efficacy in activating the receptor than other two ligands (Cole et al. 1998; Meyer et al. 2001; Sauty et al. 2001; Clark-Lewis et al. 2003; Booth et al. 2004) . Astrocytes stimulated by IFN-c and IL-1 together could enormously express CXCL11 (Cole et al. 1998) . Whether cells in the central nervous system other than astrocytes are capable of producing CXCL11 remains to be determined. Glial cells, such as microglia and astrocytes, have been identified as regulating neuronal functions by releasing various inflammatory cytokines and neurotrophic factors (Haydon 2001; Chen et al. 2012; Wang et al. 2012a,b,c) . Moreover, a relationship between astrocytes and analgesic tolerance to morphine has been recently documented (Johnston et al. 2004; Raghavendra et al. 2004; Narita et al. 2006; Harada et al. 2013) . However, whether CXCL11 is involved in the mechanism of chronic morphine-induced analgesic tolerance remains to be elucidated. Based on studies showing the roles of CXCL10 and CXCR3 in morphine tolerance, this study was designed to investigate whether CXCL11 participates in the development of morphine tolerance in CIBP rats and normal rats.
Material and methods

Animals
All experimental procedures and protocols used in this study were carried out in accordance with the National Institutes of Health guidelines and Ethical Issue of the International Association for the Study of Pain, and were reviewed and approved by the Experimental Animal Care and Use Committee of Tongji Medical College, Huazhong University of Science & Technology. Both adult female Sprague-Dawley rats (weighing 180-220 g) and neonatal SD rats (P1) were purchased from the Laboratory Animal Center, Tongji Medical College, Huazhong University of Science & Technology. Adult female SD rats were kept under controlled conditions (22 AE 0.5°C, relative humidity 40-60%, alternate light-dark cycles, food, and water ad libitum). Rats were numbered with tail markings and randomized into groups with completely random design. According to previous studies, 90 adult female SD rats were randomly divided into groups in the corresponding experiments with six rats per group (Luger et al. 2002; Bai et al. 2014; Bao et al. 2014; Ye et al. 2014; Bu et al., 2015; Song et al. 2015) . After finishing the last behavioral tests, three rats of each group were killed for western blots analysis, while the rest for immunohistochemistry (Ye et al. 2014; Song et al. 2015; Tan et al. 2015) . On the basis of ensuring the validity of experimental results, all efforts were made to reduce the number of animals used in our experiments and to minimize any possible suffering by the animals.
Drug preparations
Morphine hydrochloride, IgG antibody, and goat anti-CXCL11 neutralizing antibody were dissolved in saline. D, L-Fluorocitric acid (FC, F9634; Sigma, St Louis, MO, USA), a selective metabolic inhibitor of astrocytes, was prepared as previously described for intrathecal injection (Hayakawa et al. 2010) . Briefly, 8 mg of FC was dissolved in 1 mL of 0.1 mmol/L HCl and 2 mL of 0.1 mmol/ L Na 2 HPO 4 was added. The suspension was diluted by saline to the final concentration. The pH was adjusted to 7.4. The drug doses used in the experiments were determined based on the results of preliminary experiments.
Preparation of carcinoma cells
Walker 256 mammary gland carcinoma cells were derived from the Institute of Cancer Research, Chinese Academy of Medical Science and Peking Union Medical College, China. Tumor cells (2 9 10 7 / mL, 0.5 mL) were injected into the abdominal cavity of rats. Six to seven days later, ascitic fluid was extracted. The carcinoma cells were subsequently washed and suspended in an appropriate volume of D-Hank's solution to achieve final concentration (4 9 10 6 /mL).
D-Hank's solution was also used for inoculation in control rats.
Surgical procedure of bone cancer models A rat model of CIBP was established following previous reports (Cao et al. 2010; Hu et al. 2012b) . In brief, rats were deeply anesthetized with pentobarbital sodium (50 mg/kg, intraperitoneal injection). The right leg of the rat was shaved and the top half of the tibia was carefully exposed after disinfection with 7% iodine and 75% (v/v) ethanol. Walker 256 cells (10 lL, 4 9 10 6 /mL) were slowly injected into the intramedullary space of the right tibia in the CIBP rats, whereas an equivalent volume of D-Hank's solution was injected into the sham rats using a 10 lL Hamilton microsyringe. The syringe was left in the injection site for an additional minute to prevent the leakage of tumor cells. The injection site was sealed with bone wax after the syringe was removed. Then, the wound was closed after being carefully disinfected 75% (v/v) ethanol. Animals were placed on a warm pad until they had regained consciousness and were returned to their home cages.
Intrathecal catheters and drug administration
Intrathecal catheters were constructed and implanted using a lumbar approach, as described previously (McNally and Westbrook 1998) . Briefly, under the same surgical conditions as CIBP modeling, rats were implanted by sterile PE-10 catheters (PE-0503; Anilab Software & Instruments, Ningbo, China) into the subarachnoid cavity between L5 and L6 vertebrae. The correct subarachnoid positioning of the tip of tubing was verified by a tail-flick response. The superficial musculature of the lower back of rat was sutured after disinfection with 75% (v/v) ethanol and the catheter was tunneled subcutaneously to exit through a small incision at the back of neck. To avoid blockage of the cannula, 10 lL of saline was flushed through the catheter. Proper intrathecal location was confirmed by a temporary motor block of both hind limbs after injection of 10 lL of 2% lidocaine. The animals were allowed a 7-day recovery period before the following experiments. All drugs were intrathecally injected (i.t.) in a 10 lL volume followed by a 10 lL saline flush by using a microinjection syringe connected to an indwelling catheter.
Behavioral assessment
The investigators were blind to the experimental protocol. Animals were placed in boxes on an elevated metal mesh floor and allowed 30 min for habituation before testing. Paw withdrawal thresholds (PWTs) estimated the changes of pain threshold were assessed according to the previous study (Liu et al. 2012) . The region between foot pads in the plantar aspect of right hind paw was stimulated by von Frey filaments with ascending order of forces (2, 4, 6, 8, 10, 15, 26, 60, 100 , and 300 g; Stoelting, Wood Dale, IL, USA). Abrupt paw withdrawal, licking, or shaking were considered as positive reactions. Once a withdrawal response was positive, the test was repeated starting with the next descending filament until no response occurred. The lowest amount of force which could elicit a response was recorded as the PWT (in grams). At 30 min after the last drug injection, the PWTs of rats in each group were measured, respectively.
Immunohistochemistry and immunocytochemistry
Under deep anesthesia with pentobarbital sodium, rats received intracardial perfusion with 4% ice-cold paraformaldehyde in 0.1 M phosphate buffer saline (PBS). After perfusion, the lumbar 2-5 (L2-5) segments of the whole spinal cord were dissected and fixed in 4% paraformaldehyde in PBS for 24 h at 4°C, and were subsequently dehydrated in 30% sucrose solution in PBS overnight (Zhang et al. 2005; Niiyama et al. 2007; Xu et al. 2013) . Spinal cord sections (30 lm) were obtained in a cryostat and processed for immunofluorescence as previously described (Hu et al. 2012a) . After washing by PBS, tissue sections were penetrated with 0.3% Triton X-100 at room temperature (RT, 23AE2°C) for 15 min to increase membrane permeability and blocked with 10% bovine serum albumin for 40 min at RT (23AE2°C), followed by incubation with goat anti-CXCL11 antibody (1 : 50, AF572; R&D, Minneapolis, MN, USA) overnight at 4°C. Then, the sections were processed with donkey anti-goat cy3 (1 : 300, SA00009-3; Proteintech, Rosemont, IL, USA) for 3 h at RT (23AE2°C). Fluorescent images were captured by using a fluorescence microscope (DM2500; Leica, Mannheim, Germany). The number of immunoreactive CXCL11 was counted in a blinded fashion. Every fifth section was picked from a series of consecutive spinal cord sections, and four sections were counted for each spinal cord (Obata et al. 2004) . The stained sections were analyzed by Image Pro Plus 4 software (Media Cybernetics, Maryland, MD, USA).
For double immunofluorescence, spinal cord sections of CIBP + morphine tolerance group were incubated with a complex of goat anti-CXCL11 antibody and mouse anti-neuronal nuclei (NeuN) antibody (1 : 200, MAB377; Chemicon, Temecula, CA, USA), mouse anti-glial fibrillary acidic protein (GFAP) antibody (1 : 200, #3670; CST, Beverly, MA, USA) and mouse anti-cluster of differentiation molecule 11b antibody (1 : 50, CBL1512Z; Millipore, Bellerica, MA, USA) overnight at 4°C. Sections were rinsed and incubated with a mixture of donkey anti-goat immunoglobulin G (IgG) or donkey anti-mouse IgG green fluorescence (1 : 100, SA00003-9; Proteintech) for 3 h at RT (23AE2°C).
For immunocytochemistry, in vitro primary cultured astrocytes and neurons were fixed in 4% paraformaldehyde for 20 min and processed for immunofluorescence with goat anti-CXCL11 antibody, mouse anti-GFAP antibody, and mouse anti-NeuN antibody as shown above.
Western blot analysis
The L2-L5 spinal cord segments were quickly removed from deeply anesthetized rats, and the tissue samples were dissected and frozen in liquid nitrogen. The proteins were extracted as described previously (Shen et al. 2014) . The tissues were homogenized in a lysis buffer containing phenylmethylsulfonyl fluoride. Subsequently, homogenates were centrifuged at 12 000 g for 15 min at 4°C and supernatants of the homogenates were collected. The protein concentration of supernatants was measured by using bicinchoninic acid assay. The total protein content among samples was equalized. After being denatured by heating at 100°C for 10 min, 40 lg protein from each sample was separated by using 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and electrotransferred onto a polyvinylidene fluoride membrane. The membranes were placed in a blocking solution, which contained Tris-buffered saline with 0.1% Tween and 5% non-fat dry milk, for 90 min at RT (23AE2°C), and then incubated overnight at 4°C with goat anti-CXCL11 antibody, mouse anti-GFAP antibody, and glyceraldehyde-3-phosphate dehydrogenase (1 : 5000; Aspen, Wuhan, China), respectively. After washing with Tris-buffered saline with 0.1% Tween, the membranes were correspondingly incubated with horseradish peroxidase (HRP)-conjugated rabbit anti-goat IgG antibody (1 : 2000, AS1029; Aspen), HRP-conjugated goat anti-mouse antibody (1 : 2000, 074-1806; Byoyear Biotechnology, Shanghai, China), and HRP-conjugated goat antirabbit IgG (1 : 2000, AS1107; Aspen) for 2 h at RT (23AE2°C).
Finally, proteins were detected by enhanced chemiluminescence reagents (ECL, Beyotime, Wuhan, China), and exposed to X-ray film. The ImageJ analysis system (NIH, Bethesda, MD, USA) was used for the quantification of specific bands. The expressions of CXCL11 and GFAP were exhibited as density relative to the density of glyceraldehyde-3-phosphate dehydrogenase.
Primary cell cultures
Primary astrocytes were prepared from cerebral cortex of neonatal SD rats (P1) (Zhou et al. 2015) . The cerebral hemispheres were dissected and transferred to ice-cold D-Hank's buffer and the meninges were carefully removed. Tissues were then minced into approximately 1 mm pieces, digested in trypsin (0.025%; Invitrogen, Carlsbad, CA, USA) at 37°C for 15 min, terminated by low glucose Dulbecco's Modified Eagle's Medium (DMEM; Gibco, Grand Island, NY, USA) with 10% fetal bovine serum (FBS) (Invitrogen), and dispersed by pipetting up and down. Then, the cells were filtered through a 100 lm nylon screen, and collected by centrifugation at 3000 g for 5 min. The cell pellets were dispersed with a pipette and resuspended in DMEM containing 10% FBS. After growing at 37°C in a humidified atmosphere of 5% CO 2 and 95% air for 7-9 days, flasks were shaken to isolate astrocytes. Then astrocytes were reseeded onto 12-well culture plates with fresh medium consisting of DMEM/F-12 and 10% FBS at a density of 1 9 10 6 /well. When astrocyte cultures were comprised of cells that were > 99% GFAP-positive, morphine (1 lM, 10 lM, 100 lM, or 1000 lM) was added for stimulation for 6 days. Culture medium was changed every other day. The supernatants were collected for ELISA and cells were processed for double immunofluorescence.
Primary neurons were also prepared from cerebral cortex of neonatal SD rats (P1) . The cerebrums were dissociated carefully, digested in 0.025% trypsin for 15 min, terminated by 10% FBS-containing DMEM, and dispersed by pipetting up and down. The cell suspension was filtered through a 100 lm nylon mesh, centrifuged, and resuspended in 10% FBScontaining DMEM. The cells were seeded into poly-L-lysine-coated culture plates (12-well) at a density of 1 9 10 6 /well. The cells were cultured with fresh medium consisting of DMEM/F-12, 10% FBS, 5% CO 2 , and 95% air for 4-6 h followed by exchanging culture medium with neural basal medium with 2% B-27 serum-free supplement (Gibco) to promote the growth of neurons. The cells were cultured in humid incubator for 7 days. On day 8, the cells were treated with morphine (1 lM, 10 lM, 100 lM) for 6 days. Culture medium was changed every other day. Culture supernatants were then collected for ELISA and cells were processed for double immunofluorescence.
Enzyme linked immunosorbent assay
The rat CXCL11 ELISA kit (F15288; Westang, Shanghai, China) was used to measure the levels of CXCL11 in culture supernatants of astrocytes and neurons by following the manufacturer's instructions. Briefly, 100 lL of culture supernatants and standards were added to a 96-well plate and incubated for 90 min at 37°C followed by ABC solution for 45 min. Then, the plate was washed using the provided washing buffer, and incubated with 100 lL of 3,3 0 ,5,5 0 -Tetramethylbenzidine (TMB) substrate solution, which was stopped by 100 lL of H 2 SO 4 . The absorbance of optical density was determined at 450 nm. The CXCL11 concentration was calculated according to standard concentration curves. The levels of CXCL11 protein were presented as pg/mL.
Statistical analyses
Statistical analyses were performed using SPSS 17.0 (Chicago, IL, USA). All data are presented as the mean AE SEM. The comparison of more than two groups were evaluated based on one-way analyses of variance (ANOVA) followed by Bonferroni or Dunnett t-tests if necessary. The differences in the PWTs data between the groups were analyzed via two-way ANOVA, in which 'Time' was treated as the 'within subjects' factor and 'Treatment' was treated as the 'between subjects' factor, followed by a Student-Newman-Keuls post hoc or Dunnett's T3 test. The statistical significance was defined as p < 0.05.
Results
Experiment 1. The establishment of morphine tolerance in CIBP rats
The baselines of PWTs in rats showed no significant difference among groups (p > 0.05). It has been reported that mechanical allodynia of rats with inoculation of carcinoma cells increase in a time-dependent manner and dramatically escalate from day 6 to day 12 postoperatively (Mao-Ying et al. 2006) . Therefore, in this study, we choose day 10 after inoculation of carcinoma cells as the starting time point to use morphine for consecutive 7 days. Morphine (10 lg/10 lL) or normal saline (NS, 10 lL) was intrathecally administered twice daily from postoperative day 10 to day 16. Behavioral tests were conducted 30 min after the last drug administration on day 0, 9, 10, 12, 14, and 16 after carcinoma cells inoculation. As shown in Fig. 1 , the ipsilateral PWTs of CIBP rats were decreased when compared with NS-treated rats on postoperative day 10 to day 16 (p < 0.05). Intrathecal injection of morphine exhibited a maximal antinociceptive effect in both morphinetreated sham rats and morphine-treated CIBP rats on postoperative day 10 (p < 0.001). However, the PWTs of both sham rats and CIBP rats receiving sustained morphine began to decrease from postoperative day 12. On the postoperative day 16, the level of PWTs almost declined to the baselines, suggesting that the tolerance to morphine analgesia had been successfully established. Importantly, the extent of antinociceptive tolerance in CIBP rats exhibited more evidently than that in sham rats with morphine treatment (p < 0.05). During the experiments, there was no significant difference of PWTs between rats inoculated with D-Hank's solution and na€ ıve rats (p > 0.05).
Experiment 2. CXCL11 expression in the spinal cord was increased during the development of morphine tolerance in CIBP rats Previous microarray analysis results indicated that mRNA expression of CXCL11 was increased in the spinal cord of morphine tolerant rats when compared with control rats (unpublished data). To confirm whether CXCL11 participates in the development of morphine tolerance in CIBP animals, we examined the protein level of CXCL11 in the spinal cord on postoperative day 16 by western blots analysis and immunohistochemistry. Protein expression of CXCL11 in NS-treated CIBP rats was significantly increased when compared with the results from NS-treated and naive rats (p < 0.001). Furthermore, the protein levels of CXCL11 in chronic morphine-treated sham rats and CIBP rats were much higher than NS-treated and naive rats, respectively (p < 0.001) (Fig. 2g) . And results of CXCL11-immunoreactive intensity in immunohistochemistry were consistent with the results of western blots analysis (Fig. 2b) . Given this, it appears that CXCL11 may be involved in the development of morphine tolerance.
To determine cellular localization of CXCL11 in the spinal cord of CIBP + morphine tolerance group, double immunofluorescence of CXCL11 was performed with different cell markers, including NeuN for neurons, GFAP for astrocytes and cluster of differentiation molecule 11b for cluster of differentiation molecule 11b for microglia. The merged pictures showed that CXCL11 was predominantly distributed in the spinal dorsal horn, and was co-localized with astrocytes ( Fig. 3c) and neurons (Fig. 3f) , instead of microglia (Fig. 3i) . These results indicate that CXCL11 are produced primarily by astrocytes and/or neurons in the spinal dorsal horn. Experiment 3. Inhibition of spinal CXCL11 could attenuate the degree of morphine antinociceptive tolerance and inhibit the activation of astrocytes According to the above results, we found that CXCL11 was activated in the spinal cord in both CIBP rats with or without chronic morphine treatment. Next, we used the anti-CXCL11 neutralizing antibody to confirm the role of CXCL11 in morphine tolerance. The goat anti-CXCL11 neutralizing antibody and morphine were intrathecally administrated to normal rats twice daily for seven consecutive days. Anti-CXCL11 (200 ng/10 lL) or IgG (10 lL, as a control) was injected 30 min before morphine (10 lg/10 lL) or NS (10 lL) administration, respectively (Ye et al. 2014) . Behavioral tests were performed 30 min after the last drug administration. As shown in Fig. 4(a) , anti-CXCL11 neutralizing antibody had no effect on PWTs in NS-treated rats (p > 0.05). However, inhibiting CXCL11 function by anti-CXCL11 neutralizing antibody significantly enhanced antinociceptive effects after repeated morphine administration on day 5 and day 7 (p < 0.05).
In addition, we also detected effects of anti-CXCL11 neutralizing antibody on GFAP expression in the spinal cord by western blots analysis. As shown in Fig. 4(b) , the increase of GFAP expression in morphine-tolerant rats was significantly attenuated by pretreatment with anti-CXCL11 neutralizing antibody (p < 0.005), which suggested that anti-CXCL11 neutralizing antibody inhibited astrocytes activation induced by chronic morphine administration. CXCL11 which might release from astrocytes could promote the activation of astrocytes through certain signaling pathways in return during the development of morphine tolerance. Experiment 4. Expression of spinal CXCL11 induced by chronic morphine exposure was dependent on the activation of astrocytes and neurons Based on the above results, chronic morphine exposure could induce the up-regulation of CXCL11 in the spinal astrocytes and inhibition of CXCL11 expression by its corresponding neutralizing antibody could decrease GFAP expression in the spinal cord. Next, to further identify whether inhibiting astrocytes activation would make difference in nociceptive behaviors and CXCL11 expression in morphine-tolerant animals, FC and morphine were intrathecally administrated to rats twice daily for 7 days. Rats received FC (1.5 nmol/ 10 lL or 2 nmol/10 lL) or NS (10 lL) 30 min before the injection of morphine (10 lg/10 lL) or NS (10 lL) (Mika et al. 2009 ). Behavioral tests were performed 30 min after the last drug administration. As shown in Fig. 5(a) , FC had no effect on the PWTs in NS-treated rats (p > 0.05). Fig. 1 The effects of chronic morphine treatment mechanical on allodynia in cancer-induced bone pain (CIBP) rats. Rats received morphine (10 lg/10 lL) or normal saline (NS) (10 lL) twice daily from day 10 to day 16 after inoculation of carcinoma cells. Paw withdrawal thresholds (PWTs) were measured on postoperative 0-, 9-, 10-, 12-, 14-, and 16th day. Although chronic morphine treatment could induce morphine tolerance both in CIBP and naive rats, the PWTs in CIBP rats was much higher than those in naive rats (p < 0.05). Data are expressed as mean AE SEM. according to two-way ANOVA, in which 'Time' was treated as the 'within subjects' factor and 'Treatment' was treated as the 'between subjects' factor, followed by a Student-Newman-Keuls post hoc or Dunnett's T3 test (n = 6 each group).
Interestingly, blocking the activation of astrocytes by 2 nmol FC, not 1.5 nmol, could significantly attenuate morphineinduced antinociceptive tolerance in a dose-dependent manner (p < 0.05).
Moreover, protein expression of CXCL11 in the spinal cord after FC treatment was determined by western blots analysis and immunohistochemistry. Chronic morphine treatment, but not NS or FC treatment, significantly enhanced the expression of CXCL11 (p < 0.05) (Fig. 5b) . 2 nmol FC could inhibit CXCL11 production in the spinal cord during the development of morphine tolerance (p < 0.05), whereas 1.5 nmol FC showed no significant effect (p > 0.05). The results of immunohistochemistry demonstrated the same changes of CXC11 immunoreactivity in the spinal cord as shown in Fig. 5(c-i) .
The in vivo results of double immunofluorescence of CXCL11 demonstrated that CXCL11 was co-localized with astrocytes and neurons. To further confirm the neural cell types which could produce CXCL11 induced by morphine, primary cultured astrocytes and neurons were treated with morphine for 6 days, respectively (Ma et al. 2000) . The results showed that CXCL11 production induced by morphine was found both in astrocyte and neurons. The maximal effect of morphine on the up-regulation of CXCL11 was at the concentration of 100 lM in astrocytes (Fig. 6a) , while 1000 lM in neurons (Fig. 6e) . The results of immunocytochemical staining showed that CXCL11 was colocalized with both astrocytes and neurons (Fig. 6b-d, 6f h). Our in vitro experiments further confirmed that CXCL11 could not only be produced by astrocytes, but also by neurons after chronic morphine treatment.
Discussion
The main finding of this study is that up-regulated CXCL11 in morphine tolerance model of CIBP rats was predominantly distributed in the spinal dorsal horn astrocytes and neurons. Moreover, anti-CXCL11 neutralizing antibody expanded the analgesic effects of morphine and inhibited astrocyte activation. Our study further showed astrocytes inhibitor could alleviate morphine tolerance through reducing the expression
(g) (h) (i) Fig. 3 The co-location of CXC chemokine 11 (CXCL11) and astrocytes, neurons and microglia. Double immunofluorescence of CXCL11 was performed with cell-specific markers: neuronal nuclei (NeuN, red) for neurons, glial fibrillary acidic protein (GFAP, red) for astrocytes and cluster of differentiation molecule 11b (CD11b, red) for microglia in spinal cord of cancer-induced bone pain + morphine tolerance group. CXCL11 was co-located with astrocytes (a-c, yellow) and neurons (d-f, yellow), but not with microglia (g-i). Scale bar: 100 lm.
of CXCL11, and both primary cultured astrocytes and neurons treated with morphine could release CXCL11. In summary, CXCL11 plays an important role in the development of morphine tolerance. Many studies have attempted to elucidate mechanisms underlying the development of bone cancer pain, and the roles of chemokines have been paid much attention. Up to now, it has been reported that CCL2/CCR2, CX3CL1/ CX3CR1, CCL5/CCR5, CXCL12/CXCR4, CXCL10/ CXCR3, and CXCL1/CXCR2 participate in the development of morphine tolerance (Yin et al. 2010; Hu et al. 2012a Hu et al. ,b, 2015 Hang et al. 2013; Pevida et al. 2013; Bu et al. 2014; Xu et al. 2014a) . Meanwhile, as the mainstay treatment for CIBP in the current practice, morphine also increases the expression of chemokines, including monocyte chemoattractant protein-1, CX3CL1, CCL5, and CXCL12, and they in turn provokes antinociceptive tolerance after chronic morphine exposure (Szabo et al. 2002; Johnston et al. 2004; Zhao et al. 2012) . Our previous study reported that CXCL10 is related to acute morphine analgesia in CIBP animals . Additionally, microarray analysis detected the up-regulation of CXCL11 via locally inflaming the L5 dorsal root ganglion in rats which imitates chronic pain condition (Strong et al. 2012) . Thus, in our study, we wanted to investigate the underlying mechanisms in which CXCL11 contributes to cancer pain and morphine tolerance.
In this study, morphine was repeatedly intrathecally administrated to induce antinociceptive tolerance in both CIBP and sham-operated rats. Interestingly, the degree of morphine tolerance in CIBP rats is further remarkable when compared with sham-operated rats. This result parallels previous findings, which demonstrated that anti-nociceptive tolerance to systemic morphine could be highly enhanced in animals with pathologic injury (Christensen and Kayser 2000; Raghavendra et al. 2002) . Hence, it is well established that CIBP exhibits similar features to neuropathic pain (Honore et al. 2000; Luger et al. 2002) . Intriguingly, we discovered that the protein level of CXCL11 rose more evidently in spinal cord of CIBP rats than sham-operated rats. According to the above evidence, it is an obvious deduction that chemokines may participate in the mechanisms of both CIBP and morphine tolerance. Previous study showed that CXCL10, which shares the same receptor with CXCL11, plays a negative role in morphine analgesia induced by activating CXCL10/CXCR3 signaling (Ye et al. 2014) . Since CXCL11 has higher affinity to CXCR3 and subsequently exhibits more robust efficacy than CXCL10 (Cole et al. 1998) , we subsequently treated rats with anti-CXCL11 neutralizing antibody to determine whether CXCL11 takes part in the development of morphine tolerance. The results of behavioral tests that show inhibiting CXCL11 could diminish analgesic effects of morphine, demonstrates the vital effect of Fig. 4 The effect of inhibiting CXC chemokine 11 (CXCL11) on morphine antinociceptive tolerance in normal rats. CXCL11 inhibitor, anti-CXCL11 neutralizing antibody, was injected to normal rats 30 min before the injection of morphine. A duration of 30 min after the last drug injection, the paw withdrawal thresholds (PWTs) were accessed on day 1, 3, 5, and 7. Anti-CXCL11 antibody significantly enhanced the antinociceptive effect of morphine during the induction of morphine tolerance on day 5 and day 7 (p < 0.05). The protein level of glial fibrillary acidic protein (GFAP) in spinal cord on day 7 was examined by western blot analysis. And the expression of GFAP in morphine tolerance rats treated by anti-CXCL11 neutralizing antibody was lower than that in chronic morphine-treated rats (p < 0.005). (a) The PWTs of morphine tolerance rats after anti-CXCL11 neutralizing antibody injection (n = 6 each group). (b) The quantitative data for the expression of GFAP. The fold change for the density of GFAP was normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) for each sample, respectively (n = 3 each group). Data are expressed as mean AE SEM. *p < 0.05, **p < 0.01, ***p < 0.001 versus Ig G + normal saline (NS) group, # p < 0.05, ## p < 0.01 versus Ig G + morphine tolerance (MT) group. The differences in the PWTs data between the groups were analyzed via two-way ANOVA followed by a Student-Newman-Keuls post hoc or Dunnett's T3 test, while the different expression of GFAP were analyzed via one-way ANOVA followed by Bonferroni tests.
CXCL11 in the mechanism of morphine tolerance. Because CXCL11 could be responsible for inflammatory pain (Strong et al. 2012) , our results state that morphine tolerance and chronic pain may partly share the same mechanism.
It has been reported that CXCL11 is primarily distributed in peripheral blood leukocytes, pancreas, liver, thymus, spleen, and lung, and mainly expressed in astrocytes, microglia cells, endothelial cells, macrophages etc. (Cole et al. 1998; Mach et al. 1999; Sauty et al. 2001) . In this study, we want to clarify which types of cells in central nervous system could produce CXCL11 during the development of morphine tolerance. The results showed that morphine-induced CXCL11 was expressed in the spinal astrocytes and neurons, instead of microglia cells. And selectively blocking the function of astrocytes before morphine administration could dramatically down-regulate spinal CXCL11 expression in a dose-dependent manner and inhibit the development of morphine tolerance. Accumulated evidence has highlighted that morphine tolerance may share common mechanisms with neuropathic pain which activates glia to release neuroexcitatory substances, including excitatory amino acids, nitric oxide, and prostaglandins, and increases the levels of pro-inflammatory neuromodulator, including Interleukin-1b (IL-1b), Interleukin-6 (IL-6) and tumor necrosis factor a (TNF-a) (Mayer et al. 1999; Raghavendra et al. 2003; Snyder 2004) . Multiple opioid receptor subtypes were expressed on glia (Chang et al. 1998) . Constitutive expression of l opioid receptors on glia was enhanced by exposure to morphine. It is also supported by the fact that co-administration of glia inhibitors, such as fluorocitrate, propentophylline, and minocycline, with morphine could effectively alleviate morphine tolerance (Raghavendra et al. 2002 (Raghavendra et al. , 2003 Johnston et al. 2004; Cui et al. 2006; Watkins et al. 2007) . Taken together, it is believed that glia can be responsible to opioids upon repeated administration. In addition, we also found that CXCL11 could be released not only by astrocytes, but also by neurons, after chronic exposure to morphine in vitro. Previous study has demonstrated that morphine could elicit the release of neuronal CX3CL1 and the activation of glia (Johnston et al. 2004) . On the basis of our previous study, CXCR3, the receptor of CXCL11, is co-expressed with the marker of neurons in periaqueductal gray (PAG) under morphine tolerance condition (data not shown). Likely, chronic morphine treatment may activate the opioid receptors on both astrocytes and neurons, and up-regulated CXCL11 then bind to its receptor CXCR3 on neurons to induce the cellular adaptive change, which results in the development of morphine tolerance. Such a hypothesis may explain the phenomenon that activation of astrocytes evoked by morphine treatment was enormously inhibited by anti-CXCL11 neutralizing antibody in our experiments. Accordingly, it is tempting to speculate that CXCL11 is involved in the development of morphine tolerance by mediating the crosstalk between astrocytes and neurons.
In conclusion, we provide novel evidence that spinal CXCL11, which could be released by both astrocytes and neurons, contributes to the development of morphine tolerance. The finding has significant therapeutic implications in prophylactically inhibiting morphine tolerance. However, further studies need to be done to elucidate more details of the role of CXCL11 in the cross-talk between astrocytes and neurons in morphine tolerance. 
(g) (h) Fig. 6 Effect of morphine on CXC chemokine 11 (CXCL11) production by rat astrocytes and neurons. Primary cultured astrocytes and neurons were treated with morphine (1000, 100, 10, 1 lM; 100, 10, 1 lM) for 6 days, respectively. Cell culture supernatants were collected for CXCL11 assay by ELISA. The maximal effect of morphine on the up-regulation of CXCL11 was at the concentration of 100 lM in astrocytes, while 1000 lM in neurons. The results of double immunocytochemical staining showed that CXCL11 was co-localized with both astrocytes and neurons. (a) The production of CXCL11 from astrocytes cultures was assayed for CXCL11 by ELISA. (b-d) CXCL11 was colocated with astrocytes (yellow). (e) The production of CXCL11 from neuronal cultures was assayed for CXCL11 by ELISA. (f-h) CXCL11 was co-located with neurons (yellow). Data are expressed as mean AE SEM. *p < 0.05, ***p < 0.001 versus control group according to one-way ANOVA followed by Dunnett t-tests. (n = 6 each group). Scale bar: 100 lm.
